Drug class in one race
IP receptor (prostacyclin pathway) drugs for Pulmonary Arterial Hypertension
4 tracked IP receptor (prostacyclin pathway) drugs in the Pulmonary Arterial Hypertension race. The class explanation lives on the IP receptor (prostacyclin pathway) page; the full indication pipeline across every mechanism is on the Pulmonary Arterial Hypertension page.
2 approved / phase 42 Phase 3
Head-to-head evidence: L606 vs Ralinepag · Ralinepag vs Treprostinil · Ralinepag vs Treprostinil (Yutrepia, Liquidia)